Bioventus (BVS) Metrics: History & Chart

Bioventus Inc.(BVS)

Medical - Devices · Durham, NC

$13.21-0.31 (-2.31%)

Delayed quote: Oct 6, 2026, 10:50 AM EDT

About Bioventus Inc.

Bioventus Inc., a medical device company, focuses on relieving pain and addressing musculoskeletal therapies in the United States and internationally. The company’s product portfolio includes pain treatments, which comprise various intra-articular and hyaluronic acid injections; peripheral nerve stimulation products, such as Durolane, GELSYN-3, and SUPARTZ for the treatment of knee osteoarthritis; and Stimrouter to treat chronic peripheral pain, and TalisMann provides stimulation to the targeted peripheral nerve, as well as XCELL PRP System, a benchtop device that processes whole blood to produce high-yield PRP with a 10-minute single-spin cycle. It also offers precision bone resection for patients with degenerative spine conditions and spinal deformities, as well as enables precision ultrasonic neuro and general surgery to address brain tumors and pathologies of the liver and other organs; and bone graft substitutes, including various products that facilitate optimal bone fusion. In addition, the company provides neXus, an ultrasonic surgical system; BoneScalpel, a surgical solution enabling precise cuts in hard tissue; BoneScalpel Access, for bone removal with visualization; SonaStar system, a precise ablation and removal of soft tissue; SonaStar Elite handpiece and accessories; SonicOne, an ultrasonic cleansing and debridement system; Osteoamp, an allograft-derived bone graft for orthopedic, neurosurgical, and reconstructive bone grafting procedures; Signafuse bone graft; Purebone, a natural osteoconductive scaffold; and Reficio demineralized bone matrix. The company’s restorative therapies include minimally invasive fracture treatments and rehabilitation products. Its products also include Exogen, an ultrasound bone stimulation system. The company sells its products to healthcare institutions, physicians, patients, distributors and dealers. Bioventus Inc. was founded in 2011 and is headquartered in Durham, North Carolina.

Durham, NC

950 employees

www.bioventus.com

Healthcare / Medical - Devices

Sector: Healthcare
Industry: Medical - Devices
CEO: Robert Claypoole

View full financials

Third-Party DCF Estimate (FMP)	N/A
Price Gap vs Third-Party Estimate	N/A

7D Total Return	-3.57%
30D Total Return	-3.91%
YTD Total Return	+81.72%
1Y Total Return	+92.59%
3Y Total Return	+329.25%
5Y Total Return	-3.98%
10Y Total Return	N/A
15Y Total Return	N/A
20Y Total Return	N/A

2026	+81.72%
2025	-29.14%
2024	+99.24%
2023	+101.92%
2022	-81.99%
2021	N/A
2020

CAGR TTM	+91.99%
CAGR 3Y	+62.50%
CAGR 5Y	-0.81%
CAGR 10Y	N/A
CAGR 15Y	N/A
CAGR 20Y	N/A

PE Ratio	17.55
PE Ratio Avg TTM	40.25
PE Ratio Avg 3Y	40.25
Current VS TTM Avg	-56.40%
Current VS 3Y Avg	-56.40%
Current VS 5Y Avg	-28.39%

All Metrics

BVS Valuation Metrics

BVS Stock Price Metrics

BVS Dividend Metrics

BVS Growth Rate Metrics

BVS Discounted Cash Flow Metrics

BVS Returns By Period

BVS Yearly Returns

BVS Average Annual Returns By Period (CAGR)

BVS Revenue Metrics

BVS PE Ratio Metrics

BVS PS Ratio Metrics

BVS PB Ratio Metrics

BVS Price to Free Cash Flow Ratio Metrics

BVS Debt to Equity Ratio Metrics

BVS PEG Ratio Metrics

BVS FCF Yield

BVS Earnings Yield

BVS EBITDA Yield

BVS OCF Yield

BVS EV/EBIT Ratio Metrics

BVS EV/EBITDA Ratio Metrics

BVS EV/Assets Ratio Metrics

BVS EV/Sales Ratio Metrics

BVS Current Ratio Metrics

BVS Quick Ratio Metrics

BVS ROIC Metrics

BVS Return on Assets Metrics

BVS Return on Equity Metrics

BVS Net Profit Margin Metrics

BVS Gross Profit Margin Metrics

BVS Tax Rate Metrics

PS Ratio	1.65
PS Ratio Avg TTM	1.18
PS Ratio Avg 3Y	0.98
Current VS TTM Avg	+40.32%
Current VS 3Y Avg	+68.52%
Current VS 5Y Avg	+78.88%

PB Ratio	4.19
PB Ratio Avg TTM	3.59
PB Ratio Avg 3Y	3.23
Current VS TTM Avg	+16.84%
Current VS 3Y Avg	+29.58%
Current VS 5Y Avg	+64.20%

PFCF Ratio	10.16
PFCF Ratio Avg TTM	9.29
PFCF Ratio Avg 3Y	16.14
Current VS TTM Avg	+9.37%
Current VS 3Y Avg	-37.04%
Current VS 5Y Avg	-64.67%

Debt/Equity Ratio	1.16
Debt/Equity Ratio Avg TTM	1.67
Debt/Equity Ratio Avg 3Y	2.15
Current VS TTM Avg	-30.78%
Current VS 3Y Avg	-46.27%
Current VS 5Y Avg	-33.93%

PEG Ratio	N/A
PEG Ratio Avg TTM	N/A
PEG Ratio Avg 3Y	N/A
Current VS TTM Avg	N/A
Current VS 3Y Avg	N/A
Current VS 5Y Avg	N/A

FCF Yield	9.84%
FCF Yield Avg TTM	10.32%
FCF Yield Avg 3Y	6.48%
Current VS TTM Avg	-4.66%
Current VS 3Y Avg	+51.78%
Current VS 5Y Avg	+100.35%

Earnings Yield	5.70%
Earnings Yield Avg TTM	3.29%
Earnings Yield Avg 3Y	3.29%
Current VS TTM Avg	+73.44%
Current VS 3Y Avg	+73.44%
Current VS 5Y Avg	+53.27%

EBITDA Yield	N/A
EBITDA Yield Avg TTM	N/A
EBITDA Yield Avg 3Y	N/A
Current VS TTM Avg	N/A
Current VS 3Y Avg	N/A
Current VS 5Y Avg	N/A

OCF Yield	N/A
OCF Yield Avg TTM	N/A
OCF Yield Avg 3Y	N/A
Current VS TTM Avg	N/A
Current VS 3Y Avg	N/A
Current VS 5Y Avg	N/A

Ev/Ebit Ratio	19.28
Ev/Ebit Ratio Avg TTM	17.93
Ev/Ebit Ratio Avg 3Y	18.54
Current VS TTM Avg	+7.52%
Current VS 3Y Avg	+3.97%
Current VS 5Y Avg	-21.85%

Ev/Ebitda Ratio	11.13
Ev/Ebitda Ratio Avg TTM	9.22
Ev/Ebitda Ratio Avg 3Y	18.56
Current VS TTM Avg	+20.73%
Current VS 3Y Avg	-40.04%
Current VS 5Y Avg	-45.06%

Ev/Assets Ratio	1.77
Ev/Assets Ratio Avg TTM	1.37
Ev/Assets Ratio Avg 3Y	1.17
Current VS TTM Avg	+28.73%
Current VS 3Y Avg	+51.69%
Current VS 5Y Avg	+81.49%

Ev/Sales Ratio	2.05
Ev/Sales Ratio Avg TTM	1.63
Ev/Sales Ratio Avg 3Y	1.56
Current VS TTM Avg	+25.52%
Current VS 3Y Avg	+31.48%
Current VS 5Y Avg	+36.02%

Current Ratio	1.69
Current Ratio Avg TTM	1.66
Current Ratio Avg 3Y	1.53
Current VS TTM Avg	+1.81%
Current VS 3Y Avg	+10.65%
Current VS 5Y Avg	+11.66%

Quick Ratio	1.17
Quick Ratio Avg TTM	1.12
Quick Ratio Avg 3Y	1.01
Current VS TTM Avg	+4.39%
Current VS 3Y Avg	+15.44%
Current VS 5Y Avg	+13.91%

ROIC	11.37%
ROIC Avg 3Y	0.40%
ROIC Avg 5Y	(4.28%)
Current VS 3Y Avg	+2722.10%
Current VS 5Y Avg	+365.58%
Current VS 10Y Avg	+2535.52%

ROA	8.09%
ROA Avg TTM	1.82%
ROA Avg 3Y	(0.18%)
Current VS TTM Avg	+344.09%
Current VS 3Y Avg	+4712.87%
Current VS 5Y Avg	+3040.35%

ROE	23.86%
ROE Avg TTM	11.18%
ROE Avg 3Y	(6.05%)
Current VS TTM Avg	+113.45%
Current VS 3Y Avg	+494.56%
Current VS 5Y Avg	+311.70%

Net Profit Margin	9.36%
Net Profit Margin Avg TTM	8.17%
Net Profit Margin Avg 3Y	(0.33%)
Current VS TTM Avg	+14.55%
Current VS 3Y Avg	+2895.13%
Current VS 5Y Avg	+527.65%

Gross Profit Margin	68.00%
Gross Pft Margin Avg TTM	68.01%
Gross Pft Margin Avg 3Y	66.98%
Current VS TTM Avg	-0.01%
Current VS 3Y Avg	+1.52%
Current VS 5Y Avg	+1.39%

Tax Rate	(136.51%)
Tax Rate Avg 3Y	19.18%
Tax Rate Avg 5Y	19.18%
Current VS 3Y Avg	-811.84%
Current VS 5Y Avg	-811.84%
Current VS 10Y Avg	-1459.33%